Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
After Bite
- Development stage
- Unknown
- Lead developer
- Tender Corporation
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
After Bite is a topical antipruritic product developed and marketed by Evolan Pharma, primarily in the Nordic region. Formulated as a liquid applied via a pen-like applicator, its active ingredient is ammonia. It is indicated for the symptomatic relief of itching and skin irritation resulting from insect bites and stings, including those from mosquitoes, bees, wasps, and ants. The ammonia works as a counter-irritant and soothing agent, potentially neutralizing acidic components of insect venom to provide immediate relief. The product is available over-the-counter and is suitable for use in adults and children aged 2 years and older.
- Brand names
- After Bite
Beyond the preview
Go deeper on After Bite.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on After Bite.